para>All antipsychotics are associated with weight gain and carry the risk of metabolic SE and tardive dyskinesia.
- Managing adverse effects of antipsychotics
- Dystonic reaction (especially of head and neck): Give diphenhydramine 25 to 50 mg IM or benztropine 1 to 2 mg IM.
- Akathisia: propranolol 10 mg BID or lorazepam 0.5 mg BID
- Pseudoparkinsonism: trihexyphenidyl 2 mg BID (may be increased to 15 mg/day if needed) or benztropine 0.5 BID (range 1 to 4 mg/day)
- Akathisia (restlessness): propranolol (30 to 60 mg in divided doses) or lorazepam (range 1 to 2 mg/day)
- Neuroleptic malignant syndrome: hyperthermia, autonomic dysfunction, and extrapyramidal symptoms; requires hospitalization and supportive management (IVF and cessation of offending neuroleptic)
- Geriatric considerations: All antipsychotics carry a black box warning for increased mortality risk in elderly dementia patients.
- Adjunctive treatments
- Benzodiazepines
- May be effective adjuncts to antipsychotics during acute phase of illness
- Useful for the treatment of catatonia
- Withdrawal reactions with psychosis or seizures
- Mood stabilizers (valproic acid lithium, lamotrigine, carbamazepine): may be effective adjuncts for those with agitated/violent behavior (7,9)[A]
- Antidepressants: if prominent symptoms of depression are present
- Metformin: helps minimize risk of metabolic SE with use of AP (10)[A]
ISSUES FOR REFERRAL
- Consider in cases of suicidality, coexistence of an addiction, difficulty in engagement, or poor self-care.
- Patients with schizophrenia should receive multidisciplinary care from both a primary care physician and a psychiatrist.
- Family members often benefit from referral to family advocacy organizations such as NAMI (11)[A].
ADDITIONAL THERAPIES
Family and patient education and psychotherapy. These include specific treatments to reduce the impact of psychotic symptoms and to enhance social functioning. Cognitive-behavioral therapy has been shown to be effective for specific symptoms of schizophrenia (12)[C].
COMPLEMENTARY & ALTERNATIVE MEDICINE
No alternative therapies are validated.
SURGERY/OTHER PROCEDURES
- Electroconvulsive therapy (ECT): For patients presenting with catatonic features, the option of ECT should be considered early when insufficient response to benzodiazepines is observed (7)[B].
- Surgical interventions are not available.
INPATIENT CONSIDERATIONS
Initial stabilization focuses on maintaining a safe environment and reducing acute psychotic symptoms and agitation through the initiation of pharmacologic treatment.
Admission Criteria/Initial Stabilization
The decision to admit is usually based on the patient 's risk of self-harm or harm to others and the inability to care for self as governed by local legal statute.
Nursing
Monitor for safety concerns and establish a safe and supportive environment.
Discharge Criteria
Based on the patient 's ability to remain safe in the community. It reflects a combination of suicide risk, level of psychotic symptoms, support systems, and the availability of appropriate outpatient services.
ONGOING CARE
FOLLOW-UP RECOMMENDATIONS
- Long-term symptom management and rehabilitation depend on engagement in ongoing pharmacologic and psychosocial treatment.
- Monitoring is based on evaluation of symptoms (including safety and psychotic symptoms), looking for the emergence of comorbidities, medication side effects, and prevention of complications.
DIET
- Newer atypical antipsychotics confer a higher risk of metabolic side effects such as diabetes, hypercholesterolemia, and weight gain.
- Although there are no specific dietary requirements, attention should be paid to the high risk of development of obesity and metabolic syndrome in individuals with schizophrenia.
PATIENT EDUCATION
- National Institute of Mental Health: Schizophrenia, at www.nimh.nih.gov/health/topics/schizophrenia/index.shtml
- Helping a Family Member with Schizophrenia: www.aafp.org/afp/20070615/1830ph.html
- National Alliance on Mental Illness (NAMI): www.NAMI.org
PROGNOSIS
- Typical course is one of remissions and exacerbations. Although uncommon, there are known cases of complete remission and of refractory illness
- Negative symptoms are often most difficult to treat.
- Excessive mortality occurs due to suicide, accidents, coronary artery disease, pulmonary disease, or substance use disorders; guarded prognosis
COMPLICATIONS
- Side effects from antipsychotic medications including tardive dyskinesia, orthostatic hypotension, QTc prolongation, and metabolic syndrome
- Self-inflicted trauma and suicide
- Combative behavior toward others
- Comorbid addictions, including nicotine (13)[A]
REFERENCES
11 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, VA: American Psychiatric Association;2013.22 McGrath JJ. Variations in the incidence of schizophrenia: data versus dogma. Schizophr Bull. 2006;32(1):195 " 197.33 Riecher-R Άssler A, H €fner H. Gender aspects in schizophrenia: bridging the border between social and biological psychiatry. Acta Psychiatr Scand Suppl. 2000;102(407):58 " 62.44 Laruelle M, Kegeles LS, Abi-Dargham A. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann N Y Acad Sci. 2003;1003:138 " 158.55 Norman RM, Manchanda R, Malla AK, et al. The significance of family history in first-episode schizophrenia spectrum disorder. J Nerv Ment Dis. 2007;195(10):846 " 852.66 Fagerstr Άm K, Aubin HJ. Management of smoking cessation in patients with psychiatric disorders. Curr Med Res Opin. 2009;25(2):511 " 518.77 Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318 " 378.88 Shenton ME, Dickey CC, Frumin M, et al. A review of MRI findings in schizophrenia. Schizophr Res. 2001;49(1 " 2):1 " 52.99 Essali A, Al-Haj Haasan N, Li C, et al. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev. 2009;(1):CD000059.1010 Mizuno Y, Suzuki T, Nakagawa A, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2014;40(6):1385 " 1403.1111 Mojtabai R, Nicholson RA, Carpenter BN. Role of psychosocial treatments in management of schizophrenia: a meta-analytic review of controlled outcome studies. Schizophr Bull. 1998;24(4):569 " 587.1212 Grant PM, Huh GA, Perivoliotis D, et al. Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia. Arch Gen Psychiatry. 2012;69(2):121 " 127.1313 Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64(10):1123 " 1131.
ADDITIONAL READING
Saks E. The Center Cannot Hold: My Journey Through Madness. New York, NY: Hyperion; 2007.
SEE ALSO
Algorithm: Delirium
CODES
ICD10
- F20.9 Schizophrenia, unspecified
- F20.0 Paranoid schizophrenia
- F20.1 Disorganized schizophrenia
- F20.2 Catatonic schizophrenia
- F20.5 Residual schizophrenia
- F20.3 Undifferentiated schizophrenia
- F20.81 Schizophreniform disorder
- F20.89 Other schizophrenia
ICD9
- 295.90 Unspecified schizophrenia, unspecified
- 295.30 Paranoid type schizophrenia, unspecified
- 295.10 Disorganized type schizophrenia, unspecified
- 295.20 Catatonic type schizophrenia, unspecified
- 295.40 Schizophreniform disorder, unspecified
- 295.80 Other specified types of schizophrenia, unspecified
- 295.60 Schizophrenic disorders, residual type, unspecified
- 295.70 Schizoaffective disorder, unspecified
- 295.50 Latent schizophrenia, unspecified
- 295.00 Simple type schizophrenia, unspecified
SNOMED
- 58214004 Schizophrenia (disorder)
- 64905009 Paranoid schizophrenia (disorder)
- 35252006 Disorganized schizophrenia (disorder)
- 191542003 Catatonic schizophrenia (disorder)
- 26025008 Residual schizophrenia (disorder)
CLINICAL PEARLS
- A debilitating chronic mental illness that affects all cultures
- Schizophrenia is characterized by positive symptoms, including hallucinations such as voices that converse with/about the patient, delusions that are often paranoid, and negative symptoms, including flattened affect, loss of a sense of pleasure, loss of will/drive, and social withdrawal.
- Multidisciplinary teams to enhance patient and family coping with serious and persistent mental illness, to prevent and treat comorbidities, and to promote recovery